{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"Participants that are still alive and without Multiple Myeloma 3 years after Stem cell Transplantation.","groups":[{"description":"Busulfan with a target daily area under the curve (AUC) of 5000 with Melphalan 70 mg/m2 followed by a stem cell transplant","id":"OG000","title":"Busulfan + Melphalan"},{"description":"High-dose Melphalan 200 mg/m2/day followed by a stem cell transplant","id":"OG001","title":"Melphalan"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3 years after transplant","title":"Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Participants"}